We help pharmaceutical companies and healthcare organizations access and engage communities of color so research is more inclusive.
Community Access and Engagement
#NOWINCLUDED is our platform for building trust with communities of color and empowering them to take control of their health.
See our approach to engagement →Engagement Analytics
e-DICT is our analytical toolset that provides insight into community engagement and trial participation potential for pharmaceutical companies.
Explore our technological solution →Pre-engagement and awareness is necessary to build trust with communities of color who may be skeptical of participating in clinical research.
Acclinate increases trust and awareness of research-related health topics in communities of color through our NOWINCLUDED platform.
With our team of culturally-competent community engagement specialists, Acclinate engages most likely participants of specific research-related health issues (e.g., health disparities, common misdiagnoses, sources of information, options for care).
Acclinate's predictive analytics tool, e-DICT, helps pharmaceutical companies and health organizations present their trial to likely participants, driving down recruitment costs and increasing diverse enrollment.
Month-over-month community growth
Accessed community members in the NOWINCLUDED ecosystem
Average diversity target for current client studies
Acclinate's predictive analytics software, e-DICT, helps pharmaceutical companies and health organizations identify and hyper-target likely participants for their clinical research, driving down recruitment costs and increasing diverse enrollment.
Contact us here →"Trust is driven by relationships. The key to diversity is inclusion, we strive to include minorities in conversations, not as a statistic, as a human being."
Tiffany Whitlow
Co-Founder, CDO
Acclinate
“We partnered with Acclinate because their platform and services will lead to successful recruitment and engagement of study participants for our first of its kind, ARGONAUT study.”
Stephanie Culler, Ph.D.
Co-Founder, CEO
Persephone Biosciences, Inc.
“Acclinate is at the forefront of implementing a portal to make certain minorities are included in clinical trials.”
Randall Moreadith, MD, PhD
President
Serina Therapeutics